Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
NEW YORK, March 28, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. (“Regulus”) (NASDAQ:RGLS) between February 17, 2016 and January 27, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Jin v. Regulus Therapeutics Inc., et al. (Case No. 17cv0267 LAB JMA) in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/regulus-therapeutics?wire-3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Regulus made materially false and/or misleading statements and/or failed to disclose that: (i) RG-101 was not safe and well tolerated by all patients in the ongoing studies, (ii) cases of serious adverse events (“SAE”) were discovered, (iii) the SAEs were proof of serious concerns about the safety profile of RG-101, (iv) Regulus would likely need to produce extensive data to the U.S. Food and Drug Administration (“FDA”) to continue clinical trials of RG-101, and (v) as a result of the foregoing, Defendants’ statements about Regulus’ business and prospects were false and misleading and/or lacked a reasonable basis.
Take Action: if you suffered a loss in Regulus you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
